Updates on CAR T-cell Therapy for Relapsed/Refractory B-Cell Lymphomas

CAR T-cell therapy represents a major paradigm shift from the conventional management strategies for relapsed or refractory B-cell lymphomas. Multidisciplinary approach is required for appropriate patient selection and management of acute toxicities to prevent fatal outcomes in patients receiving CAR-T-cell therapy. There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of adverse events and effective management strategies. More importantly, clinicians should refer appropriate patients for participation in well-designed clinical studies to facilitate the development of CAR T-cell therapies.

Target Audience

The program is designed to meet the needs and improve the competence and performance of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals who manage the care of patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe the current treatment approach and the rationale for the development of novel treatment options for relapsed/refractory B-cell lymphomas.
  • Review the efficacy of currently approved as well as investigational CAR T-cell therapies for relapsed or refractory B-cell lymphomas.
  • Evaluate the strategies for the management of unique toxicities associated with CAR T-cell therapies, and integrate CAR T-cell therapy into the overall treatment plan in appropriate patients with relapsed or refractory B-cell lymphomas. 
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Abbott's molecular business
  • Adaptive Biotechnologies
  • AstraZeneca
  • BeiGene, Ltd.
  • Blueprint Medicines
  • Daiichi Sankyo
  • Deciphera Pharmaceuticals
  • Eisai
  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Gilead Sciences
  • GlaxoSmithKline
  • GRAIL, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Lilly
  • Olympus Corporation of the Americas
  • Novartis
  • Pfizer
  • Puma Biotechnology
  • Seagen Inc. formerly Seattle Genetics
  • Taiho Oncology, Inc.
  • TeSera Therapeutics

This activity is supported by independent medical education grants from: 

  • Bristol Myers Squibb 
  • Illumina, Inc. 
  • Regeneron Pharmaceuticals, Inc and Sanofi Genzyme

This activity is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Incyte
  • Merck & Co., Inc.

This activity is supported by educational funding provided by Amgen.

This educational activity is supported by a medical education grant from Exelixis, Inc. & Karyopharm® Therapeutics.

This project has been made possible in part by a grant from Varian Medical Systems/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
05/20/2021
Course expires: 
03/01/2022
Cost:
$0.00

Stephen J. Schuster, MD
Abramson Cancer Center at the University of Pennsylvania

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care.  Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. 

Definitions  

NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Stephen J. Schuster, MD
Allogene Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Celgene Corporation: Consulting Fee; Scientific Advisor
Genentech, Inc.: Scientific Advisor; Grant/Research Support; Consulting Fee
Incyte Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Legend Biotech: Consulting Fee
Loxo Oncology, Onc.: Scientific Advisor; Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor; Grant/Research Support; Consulting Fee; Honoraria
Regeneron Pharmaceuticals, Inc.: Consulting Fee

Moderator Disclosures

The faculty listed below discloses the following relevant financial relationships:

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Scientific Advisor
Adaptive Biotechnology: Consulting Fee
Amgen Inc.; Consulting Fee
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BeiGene: Scientific Advisor
BMS/Celgene/Juno: Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Scientific Advisor
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Janssen Pharmaceutical Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support

NCCN Staff Disclosures

The NCCN Leadership listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Mary A. Dwyer, MS, CGC; Hema Sundar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Pharmacists
NCCN designates this application-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-073-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing